VigiPallia : Résultats

RADIOTHERAPIE

0 sélectionnée(s) / 282 réponse(s)

(1) 2 3 4 ... 15 > »

Palliative radiation therapy in older adults with cancer - age-related considerations

O'DONOVAN, A. ; MORRIS, L.
Clinical oncology, 06/07/2020, 9 p.

Document en ligne

Feasibility and effectiveness of palliative intensity-modulated radiotherapy for carotid sinus syndrome secondary to recurrent head and neck cancer

WADA, Kentaro ; HIRATA, Takero ; SHINODA, Yuichiro ; TESHIMA, Teruki
BMJ case reports, 30/06/2020, vol.13, n°6, Pagination inconnue

Document en ligne

Palliative care physicians and palliative radiotherapy, knowledge and barriers for referring - a cross-sectional study

VARGAS, Andrés ; TORRES, Carolina ; KULLER-BOSCH, Anna ; VILLENA, Belén
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 29/06/2020, 10 p.

Document en ligne

Palliative lung radiotherapy - higher dose leads to improved survival?

LEWIS, T. S. ; KENNEDY, J. A. ; PRICE, G. J. ; MEE, T. ; WOOLF, D. K. ; BAYMAN, N. A. ; CHAN, C. ; COOTE, J. H. ; FAIVRE-FINN, C. ; HARRIS, M. A. ; HUDSON, A. M. ; PEMBERTON, L. S. ; SALEM, A. ; SHEIKH, H. Y. ; MISTRY, H. B. ; COBBEN, D. C. P.
Clinical oncology, 26/06/2020, p. 1-11

Document en ligne

Physician-predicted prognosis and palliative radiotherapy treatment utilization at the end-of-life - an audit of a large cancer center network

MOJICA-MARQUEZ, Adrianna E. ; RODRIGUEZ-LOPEZ, Joshua L. ; PATEL, Ankur K. ; LING, Diane C. ; RAJAGOPALAN, Malolan S. ; BERIWAL, Sushil
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 26/06/2020, p. 1-53

Document en ligne

30-day mortality following palliative radiotherapy

KAIN, Mollie ; BENNETT, Hayley ; YI, Ma ; ROBINSON, Bridget ; JAMES, Melissa
Journal of medical imaging and radiation oncology, 27/06/2020, Pagination inconnue

Document en ligne

External validation of life expectancy prognostic models in patients evaluated for palliative radiotherapy at the end-of-life

MOJICA-MARQUEZ, Adrianna E. ; RODRIGUEZ-LOPEZ, Joshua L. ; PATEL, Ankur K. ; LING, Diane C. ; RAJAGOPALAN, Malolan S. ; BERIWAL, Sushil
Cancer medicine, 26/06/2020, p. 1-7

Document en ligne

Risk factors for severe gastrointestinal toxicity in patients receiving palliative radiotherapy for metastatic bone tumors - association with the use of molecular-targeted agents

MURAKAMI, Yuji ; KENJO, Masahiro ; ISHIKAWA, Kazuki ; SAKAYAUCHI, Toru ; ITASAKA, Satoshi ; NEGORO, Yoshiharu ; JINGU, Keiichi ; NISHIMURA, Yasumasa ; NAGATA, Yasushi ; OGAWA, Kazuhiko
Journal of radiation research, 22/06/2020, p. 1-6

Document en ligne

Randomized controlled trial to identify the optimal radiotherapy scheme for palliative treatment of incurable head and neck squamous cell carcinoma

AL-MAMGANI, Abrahim ; KESSELS, Rob ; VERHOEF, Cornelia G. ; NAVRAN, Arash ; HAMMING-VRIEZE, Olga ; KAANDERS, Johannes H. A. M. ; STEENBAKKERS, Roel J. H. M. ; TANS, Lisa ; HOEBERS, Frank ; ONG, Francisca ; VAN WERKHOVEN, Erik ; LANGENDIJK, Johannes A.
Radiotherapy and oncology, 08/2020, vol.149, p. 181-188

Document en ligne

National quality improvement participation among US radiation oncology facilities - compliance with guideline-concordant palliative radiotherapy for bone metastases

DINH, Tru-Khang T. ; FORD, Eric ; HALASZ, Lia M. ; LEE, Christoph I.
International journal of radiation oncology, biology, physics, 11/05/2020, Pagination inconnue

Document en ligne

Risk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer

NIEDER, Carsten ; IMINGEN, Kristian S. ; MANNSAKER, Bård ; YOBUTA, Rosalba ; HAUKLAND, Ellinor
Radiation oncology, 01/05/2020, vol.15, n°1, p. 1-6

Document en ligne

Thème : Médecine. Cote : eD03.01.01

RADIOTHERAPIE ; SYMPTOME DIGESTIF ; ETUDE RETROSPECTIVE ; CANCER RESPIRATOIRE

Introduction: Esophagitis influences quality of life and might cause treatment interruption and hospitalization. Previous studies of risk factors focused on curative treatment for non-small cell lung cancer (NSCLC), which often involves concomitant chemoradiation (CRT). Given the uncertainty around extrapolation of dose constraints, we analyzed risk factors in patients treated with hypofractionated palliative regimens.
Patients and methods: A retrospective review of 106 patients treated with palliative radiotherapy or CRT between 2009 and 2017 was performed. Inclusion criteria: prescribed total dose 30–54 Gy, dose per fraction 2.5–4 Gy, esophageal dose > 1 Gy. Uni- and multivariate analyses were performed in 97 eligible patients to identify predictive factors for acute esophagitis grade = 1 (CTCAE 5.0).
Results: Forty percent of patients were treated with 15 fractions of 2.8 Gy (42 Gy) and 28% also received chemotherapy according to the CONRAD study regimen (induction and concomitant Carboplatin/Vinorelbine) published by the Norwegian Lung Cancer Group. Thirty-four percent were treated with 10 fractions of 3 Gy. Stage IV NSCLC was present in 47%. Esophagus Dmax was 39 Gy (population median) and Dmean 15 Gy. Overall 31% of patients developed esophagitis (26% grade 2–3, no grade 4–5). Several dosimetric parameters correlated with the risk of esophagitis (Dmax, Dmean, D5cc, V20, V30, V35, V40). Dmax outperformed other dosimetric variables in multivariate analysis. Furthermore, concomitant chemotherapy significantly increased the risk of esophagitis, while oral steroid medication reduced it. In patients with Dmax =40 Gy a reduced Dmean (=20 Gy) was beneficial.
Conclusion: In order to reduce esophagitis after hypofractionated palliative treatment lower doses than those recommended in curative NSCLC settings are preferable. Besides esophageal dose, CRT is the main risk factor for esophagitis. Additional work is needed to confirm that steroids are able to modify the risk (or to rule out confounding effects of baseline variables not included in our database).

Origine : PubMed

Trends in provision of palliative radiotherapy and chemotherapy among hospices in the United States, 2011-2018

HSU, Sylvia H. ; WANG, Shi-Yi
JAMA oncology, 30/04/2020, Pagination inconnue

Document en ligne

The use of patient reported outcome measures (PROMs) in palliative radiotherapy - a topical review

OLDENBURGER, E. ; OLDENBURGER, F. ; COOLBRANDT, A. ; ISEBAERT, S. ; NEYENS, I. ; SEVENANTS, A. ; VAN AUDENHOVE, Ch ; HAUSTERMANS, K.
Radiotherapy and oncology, 08/2020, vol.49, p. 94-103

Document en ligne

Palliative radiotherapy for oncologic emergencies in the setting of Covid-19 - approaches to balancing risks and benefits

YERRAMILLI, Divya ; XU, Amy J. ; GILLESPIE, Erin F. ; SHEPHERD, Annemarie F. ; BEAL, Kathryn ; GOMEZ, Daniel ; YAMADA, Josh ; TSAI, C. Jillian ; YANG, T. Jonathan
Advances in radiation oncology, 08/04/2020, p. 1-6

Document en ligne

Sticky stuff - xerostomia in patients undergoing head and neck radiotherapy-prevalence, prevention, and palliative care

SNIDER, James William ; PAINE, Charles Christian
Annals of palliative medicine, 04/2020, vol.9, n°4, p. 949-949

Document en ligne

Prediction model for short-term mortality after palliative radiotherapy for patients having advanced cancer - a cohort study from routine electronic medical data

LEE, Shing Fung ; LUK, Hollis ; WONG, Aray ; NG, Chuk Kwan ; WONG, Frank Chi Sing ; LUQUE-FERNANDEZ, Miguel Angel
Scientific reports, 2020, vol.10, n°1, p. 1-10

Document en ligne

Unexpected response to palliative radiotherapy for subcutaneous metastases of an advanced small cell pancreatic neuroendocrine carcinoma - a case report of two different radiation schedules

CILIBERTI, Maria Paola ; CARBONARA, Roberta ; GRILLO, Antonietta ; LEO, Anna Maria ; LOLLI, Ivan ; OSTUNI, Carmela ; TROIANI, Laura ; TURI, Barbara ; VALLARELLI, Simona ; SARDARO, Angela
BMC Cancer, 12/2020, vol.20, n°1, p. 1-7

Document en ligne

Adapting palliative radiation therapy for bone metastases during the Covid-19 pandemic - GEMO position paper

THUREAU, Sébastien ; FAIVRE, Jean Christophe ; ASSAKER, Richard ; BIVER, Emmanuel ; CONFAVREUX, Cyrille B. ; DEBIAIS, Françoise ; DUTERQUE-COQUILLAUD, Martine ; GIAMMARILE, Fransesco ; HEYMANN, Dominique ; LECOUVET, Frédéric E. ; MORARDET, Laetitia ; PAYCHA, Frederic ; BODY, Jean-Jacques ; VIEILLARD, Marie-Hélène
Journal of bone oncology, 04/2020, p. 1-8

Document en ligne

ABRAVAN, Azadeh ; EIDE, Hanne Astrid ; HELLAND, Aslaug ; MALINEN, Eirik
Clinical and translational radiation oncology, 05/2020, vol.22, p. 15-21

Document en ligne

Thème : Médecine. Cote : eD03.02

RADIOTHERAPIE ; CANCER RESPIRATOIRE ; THERAPEUTIQUE ANTI CANCEREUSE ; HEMATOLOGIE

Background: Lymphopenia during radiotherapy (RT) may have an adverse effect on treatment outcome. The aim of this study is to investigate associations between lymphopenia and RT parameters in patients with advanced lung cancer. Moreover, to investigate the prognostic role of lymphopenia, blood protein levels, and treatment and patient-related factors.
Material and Methods: Sixty-two advanced stage non-small cell lung cancer (NSCLC) patients were retrospectively analyzed. Blood counts were available prior to, during, and after RT (3Gyx10). For each patient, a thoracic volume of interest (VOI) -including thoracic soft tissue and trabecular bone- was obtained by applying a CT window of -500 to 1200 HU in the planning CT. Dose parameters from thoracic VOI and other regions including lungs and vertebrae were calculated. Association between risk of lymphopenia = G3 (lymphocytes at nadir according to CTCAE v4.0) and therapeutic parameters was investigated using Logistic regression. Relationships between overall survival (OS) and RT dose parameters, baseline blood counts and protein levels, and clinical factors were evaluated using Log-rank and Cox models.
Result: Mean thoracic RT dose (odds ratio [OR] 1.67; p = 0.04), baseline lymphocytes (OR 0.65; p = 0.01), and corticosteroids use (OR 6.07; p = 0.02) were significantly associated with increased risk of lymphopenia = G3 in multivariable analysis. Worse OS was associated with high mean thoracic RT dose, high CRP/Albumin, large tumor volume and corticosteroids use (p < 0.05, univariate analysis), but not with lymphopenia = G3. CRP/Albumin ratio > 0.12 (hazard ratio [HR] 2.28, p = 0.03) and corticosteroid use (HR 2.52, p = 0.01) were independently associated with worse OS.
Conclusion: High thoracic RT dose gave a higher risk of lymphopenia = G3; hence limiting dose volume to the thorax may be valuable in preventing severe lymphopenia for patients receiving palliative fractionated RT. Still, lymphopenia = G3 was not associated with worse OS. however, high baseline CRP/Albumin was associated with poorer OS and may carry important information as a prognostic factor of OS in advanced NSCLC receiving palliative RT.

Origine : PubMed

Radiation oncology should be a partner to medical oncology in end-of-life care

MCCLELLAND, Shearwood ; MITIN, Timur
Reports of practical oncology and radiotherapy, 04/2020, vol.25, n°2, p. 155-156

Document en ligne

(1) 2 3 4 ... 15 > »

Actions

##titre_notice##